The FDA has approved more generics the past few years, but a flood of new applications has steadily added to the demand. And critics say getting generic alternatives to the U.S. market for products like EpiPen is still taking far too long.
Government Solution Not Needed to Reduce Drug Costs
August 25, 2022
In a recent article in the Bristol Herald Courier, David Balto gives a great summary of the problems with the pharmacy benefit management industry, such
